Plasminogen Activator Inhibitor Type 1 Deficiency


  1. Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor: Evidence for ‘second site’ interactions. Biochemical Journal. 1988;25:327-32.
  2. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thrombosis Research. 1983;31:427-36.
  3. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005;93:631-40.
  4. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-33.
  5. Simpson A, Booth N, Morore N, Bennet B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. British Journal of Haematology. 1990;75:534-8.
  6. Preissner K, Holzhuter S, Justus C, Muller-Berghaus G. Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood. 1989;74:1989-96.
  7. Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett. 1988;242.
  8. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988;263:15454-61.
  9. Astedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thrombosis and Haemostasis. 1985;53:122-5.
  10. Kopitar M, Rozman B, Babnik J, Turk V, Mullins DE, Wun TC. Human leucocyte urokinase inhibitor–purification, characterization and comparative studies against different plasminogen activators. Thromb Haemost. 1985;54:750-5.
  11. Nilsson I, Felding P, Lecander I, Lenner C, Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. British Journal of Haematology. 1986;62:215-20.
  12. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987;69:460-6.
  13. Erickson LA, Schleef RR, Ny T, Loskutoff DJ. The fibrinolytic system of the vascular wall. Clin Haematol. 1985;14:513-30.
  14. Dano K, Adreasen P, Grondahl-Hansen, Kristensen P, Nielsen L, Skriver L. Plasminogen activators, tissue degradation, and cancer. Advances in Cancer Research. 1985;44:139-266.
  15. Loskutoff D, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Progress in Hemostasis and Thrombosis. 1989;9:87-115.
  16. Kohler H, Grant P. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792-801.
  17. Konstantinides S, Schäfer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576-83.
  18. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis. 2005;3:35-45.
  19. Vassalli J, Sappino A, Belin D. The plasminogen activator/plasmin system. Journal of Clinical Investigation. 1991;88:1067-72.
  20. Fay W, Parker A, Condrey L, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 1997;90:204-8.
  21. Beers WH, Strickland S, Reich E. Ovarian plasminogen activator: Relationship to ovulation and hormonal regulation. Cell. 1975;6:387-94.
  22. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. Journal of Clinical Investigation. 1993;92:2746-55.
  23. Carmeliet P, Stassen J, Schoonjans L, Ream vdO. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. Journal of Clinical Investigation. 1993;92:275-60.
  24. Hagege J, Peraldi M, Rondeau E, Adida C, Delarue F, Medcalf R, et al. Plasminogen activator inhibitor-1 deposition in the extracellular matrix of uncultured human mesangial cells. American Journal of Pathology. 1992;141:117-28.
  25. Seiffert D, Mimuro J, Schleef R, Loskutoff D. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differentiation and Development. 1990;32:287-92.
  26. Ehrlich H, Gebbink R, Keijer J, Linders M, Presissner K, Pannekoek. Alteration of serping specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thombin inhibitory properties. Journal of Biological Chemistry. 1990;265:13029-55.
  27. Ehrlich H, Gebbink R, Preissner K, Keijer J, Esmon N, Mertens K, et al. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronecting in the endothelial cell matrix. Journal of Cell Biology. 1991;115:1773-81.
  28. Eitzman D, McCoy R, Zheng X, Fay W, Shen T, Ginsburg D, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the muring plasminogen activated inhibitor-1 gene. Journal of Clinical Investigation. 1996;97:232-7.
  29. Eren M, Boe AE, Klyachko EA, Vaughan DE. Role of plasminogen activator inhibitor-1 in senescence and aging. Semin Thromb Hemost. 2014;40:645-51.
  30. Flevaris P, Vaughan D. The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis. Semin Thromb Hemost. 2017;43:169-77.
  31. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. Journal of cellular physiology. 2012;227:493-507.
  32. Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, et al. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation. 2010;122:1200-9.
  33. Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood. 2010;115:2038-47.
  34. Flevaris P, Khan SS, Eren M, Schuldt AJT, Shah SJ, Lee DC, et al. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-beta and Cardiac Fibrosis. Circulation. 2017;136:664-79.
  35. Gupta S, Khan S, Shah S, Heiman M, Klyachko E, Baldridge AS, et al. ABSTRACT PB 1996: Association of homozygous PAI-1 deficiency with cardiac fibrosis in humans. Research and Practice in Thrombosis and Haemostasis. 2017;1:846-.
  36. Heiman M, Gupta S, Khan SS, Vaughan DE, Shapiro AD. Complete plasminogen activator inhibitor 1 deficiency. In: [Internet] G, ed., 2017.
  37. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma sevels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:33-7.
  38. Sartori M, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi G. 4/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thrombosis and Haemostasis. 1998;80:956-60.
  39. Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Archives of Pathology & Laboratory Medicine. 2002;126:1401-4.
  40. Seguí R, Estellés A, Mira Y, España F, Villa P, Falcó C, et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. British Journal of Haematology. 2000;111:122-8.
  41. Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Binder B. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thormboembolism. Thrombosis and Haemostasis. 1998;79:975-9.
  42. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-63.
  43. Lijnen HR, Collen D. Impaired fibinolysis and the risk for coronary heart disease. Circulation. 1996;94:2052-4.
  44. Rocha E, Alfaro M, Paramo J, Canadell J. Preoperative identification of patients at high risk of deep venous thrombosis desite prophylaxis in total hip replacement. Thrombosis and Haemostasis. 1988;59:93-5.
  45. Meltzer M, Doggen C, de Groot P, Rosendaal F, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Seminars in Thrombosis and Hemostasis. 2009;35:468-77.
  46. Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immunology Letters. 2008;118:116-24.
  47. Glueck C, Kupferminc M, Fontaine R, Wang P, Weksler B, Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstetrics and Gynecology. 2001;97:44-8.
  48. Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, et al. Prognostic significance of urokinose plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph nodes- and hormone receptor-positive breast cancer. BMC Cancer. 2006;31:216.
  49. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14:1255-60.
  50. Ågren A, Wiman B, Stiller V, Lindmarker P, Sten-Linder M, Carlsson A, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemostasis. 2006;4:201-8.
  51. Santamaria A, Borrell M, Mateo J, Vallve C, Fontcuberta J. What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. Journal of Thrombosis and Haemostasis. 2007;5:1565-6.
  52. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989;83:1747-52.
  53. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729-33.
  54. Kuhli C, Lüchtenberg M, Scharrer I, Hattenbach L-O. Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefe’s Arch Clin Exp Ophthalmo. 2005;243:963-6.
  55. Lee M, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993;81:2357-62.
  56. Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Maki I, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis. 1999;29:286-91.
  57. Morimoto Y, Yoshioka A, Imai Y, Takahashi Y, Minowa H, Kirita T. Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1. Haemophilia. 2004;10:669-74.
  58. Takahashi Y, Tanaka T, Minowa H, Ookubo Y, Sugimoto M, Nakajima M, et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol. 1996;64:61-8.
  59. Zhang Z, Wang Z, Dong N, Bai X, Zhang W, Ruan C. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis. 2005;16:79-84.
  60. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof E. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991;77:528-32.
  61. Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost. 2011;9:1200-6.
  62. Iwaki T NK, Kobayashi T, Umemura K, Terao T, Kanayama N. The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in human. Thrombosis Research. 2012;129:e161-e3.
  63. Iwaki T, Nagahashi K, Takano K, Suzuki-Inoue K, Kanayama N, Umemura K, et al. Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation. Thromb Haemost. 2017;117:860-9.
  64. Kahl B, Schwartz B, Mosher D. Profound imbalance of pro-fibrinolytic and anti-fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a pateint with cirrhosis: correction by liver transplantation. Blood Coagul Fibrinolysis. 2003;14:741-4.
  65. Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thrombosis Research. 2007;119:715-21.
  66. Francis R, Leibman H, Koehler S, Feinstein D. Accelerated fibrinolysis in amyloidosis: specific binding of tissue plasminogen activator inhibitor by an amyloidogenic monoclonal Igg [Abstract]. Blood. 1986;68:333a.
  67. Repine T, Osswald M. Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review. Clin Appl Thromb Hemost. 2004;10:293-6.
  68. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circulation research. 1990;67:1281-6.
  69. Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. Haemophilia. 2014;20:407-12.
  70. Ichinose A, Asahina T, Kobayashi T. Congenital blood coagulation factor XIII deficiency and perinatal management. Current drug targets. 2005;6:541-9.
  71. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstetrical & gynecological survey. 2007;62:255-60
  72. Iwaki T, Castellino FJ. Maternal fibrinogen is necessary for embryonic development. Current drug targets. 2005;6:535-9.
  73. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101-6.
  74. Huang J, Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin S-Y, Ding J, et al. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood. 2012;120:4873-81.
  75. Schoenhard J, Smith L, Painter C, Eren M, Johnson C, Vaughan D. Regulation of the PAI-1 promoter by circadian clock components: differential activiation by BMAL1 and BMAL2. Journal of Molecular and Cellular Cardiology. 2003;35:473-81.
  76. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol. 2000;20:1682-7.
  77. Grames M, Breviario F, Pintucci G, Millet I, Dejana E, van Damme J, et al. Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. Biochemical and biophysical research communications. 1986;139:720-7.
  78. Hosoya S, Ohbayashi E, Matsushima K, Takeuchi H, Yamazaki M, Shibata Y, et al. Stimulatory effect of interleukin-6 on plasminogen activator activity from human dental pulp cells. Journal of endodontics. 1998;24:331-4.
  79. Martin NB, Jamieson A, Tuffin DP. The effect of interleukin-4 on tumour necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Thromb Haemost. 1993;70:1037-42.
  80. Baars JW, de Boer JP, Wagstaff J, Roem D, Eerenberg-Belmer AJ, Nauta J, et al. Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br J Haematol. 1992;82:295-301.
  81. D’Angelo A, Kluft C, Verheijen JH, Rijken DC, Mozzi E, Mannucci PM. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. European journal of clinical investigation. 1985;15:308-12.
  82. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420-5.
  83. Crandall DL, Quinet EM, Morgan GA, Busler DE, McHendry-Rinde B, Kral JG. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. The Journal of clinical endocrinology and metabolism. 1999;84:3222-7.
  84. Brussaard HE, Gevers Leuven JA, Frolich M, Kluft C, Krans HM. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia. 1997;40:843-9.
  85. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I’nfarctus du Mycocarde. Thromb Haemost. 1995;74:837-41.
  86. Orphanet. Congenital plasminogen activator inhibitor type 1 deficiency patient organisations. 2013.